Drug intelligence / Profile preview

endostar + envafolimab + β-glucan

Development stage: Unknown
Lead developer: Simcere Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous, Intravenous

Overview

A combination therapy consisting of Endostar (recombinant human endostatin), Envafolimab (a subcutaneously injected PD-L1 immune checkpoint inhibitor), and β-glucan. This regimen is being investigated for immune rechallenge in metastatic non-small cell lung cancer (NSCLC) patients who previously failed anti-PD-1 treatment. The combination works through multiple mechanisms: β-glucan helps reverse resistance to anti-PD-1/PD-L1 inhibitors by regulating the tumor microenvironment, Envafolimab blocks the PD-1/PD-L1 pathway to restore anti-tumor immune response, and Endostar provides anti-angiogenic effects.

Targets

CLEC7A (Dectin-1)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on endostar + envafolimab + β-glucan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on endostar + envafolimab + β-glucan.

Explore the full profile